AARD vs BZFD โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
AARD Captures Institutional Edge (2โ1 Pillars ยท 4โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Aardvark Therapeutics, Inc. Common Stock (AARD) driven by superior Growth & Margin, Options & Structure while BZFD counters with relative strength in Momentum & Technical. Fundamentally, AARD trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus BZFD at N/M Forward P/E and -17.7% operating margin (-43.8% YoY). In options structure, AARD sits in UNCLASSIFIED (26th %ile IV; Dealer Gamma Walls on Pro) against BZFD sits in BREAKDOWN (50th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | AARD | BZFD | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $21.9M | $38.1M | Larger Scale | BZFD |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | -43.8% | Higher Growth | AARD |
| Operating Margin (TTM) Profitability | 0.0% | -17.7% | Higher Margin | AARD |
| Net Profit Margin Profitability | 0.0% | -48.0% | Higher Margin | AARD |
| Return on Equity (ROE) Capital Efficiency | -66.0% | -123.0% | Higher ROE | AARD |
| 52-Week Range Position Momentum | 0% ($1โ$17) | 2% ($0โ$2) | Stronger Trend | BZFD |
| Beta / 30D Volatility Risk Regime | 3.84ฮฒ ยท 284% Vol | 2.52ฮฒ ยท 192% Vol | Lower Realized Risk | BZFD |
| Unified Institutional Score Composite Signal | 45.9 / 100 (HOLD) | 51.3 / 100 (HOLD) | Higher Composite | BZFD |